- Healthcare Professionals
- Research
- Clinical trials
- Phase 2 study of zandelisib in subjects with follicular lymphoma or marginal zone lymphoma
Cancer
The Tidal study
A Multicenter, Open-Label, Single-Arm, Phase 2 Study of Zandelisib in Subjects with Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies
Trial overview
Description
This is a global, multicenter open-label, single-arm, Phase 2 study of the PI3Kδ inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic therapy which must have included an anti-CD20 antibody and chemotherapy with an alkylating agent or a purine analogueApproximately 180 subjects will be enrolled and treated with Zandelisib (ME-401) on the intermittent schedule.
Study details
For detailed information on this trial, please click here
Trial status
Actively recruiting
Location
Principle Investigator
